The Ministry of Health and the National Emergency Commission (CNE) reported that Costa Rica signed an agreement with the companies Pfizer and BioNTech, a German company, to supply its candidate BNT162b2 vaccine against SARSCoV-2.
This vaccine is mRNA-based, patented by BioNTech and supported by Pfizer’s global vaccine development and manufacturing capabilities, and is subject to successful clinical study and regulatory approval.
The government of Costa Rica would receive 3 million doses, after authorization from the Ministry of Health, so it could have coverage to grant two applications to one and a half million people. Financial details of the deal were not disclosed given the business confidentiality required by the companies.
This purchase would be achieved through the National Emergency Fund through the exception path allowed by emergency law 8488.
At the request of the Costa Rican government, deliveries would be made progressively in 2021, beginning in the first quarter of that year, subject to clinical success and local regulatory approval.
This agreement joins the announcement of Costa Rica’s adhesion to the COVAX-Facility mechanism, which provides for a population coverage of just over one million people. With this, Costa Rica would be guaranteeing vaccination for two and a half million Costa Ricans.